G1 Therapeutics Inc. (Pending:GTHX) filed its S-1/A with the Securities and Exchange Commission for its upcoming initial public offering.
We highlighted the deal on our IPO Insights platform.
The company intends to sell 6.25 million shares at a marketed price range of $15 to $17. It has an additional 937,500 shares as an overallotment option for its underwriters. If GTHX prices at the midpoint of its proposed range, it could have a market capitalization of $442M.
The underwriters for the IPO are J.P. Morgan, Cowen and Company, Needham & Company and Wedbush PacGrow.
Business overview
(www.g1therapeutics.com/pages/pipeline/pi…)
G1 Therapeutics Inc. is a biotechnology company that is focused on developing innovative therapies for the treatment of cancer. The clinical-stage company has two primary products that are cyclin-dependent kinase inhibitors for CDK4 and CDK6. Its most advanced product candidate is Trilaciclib, which is an intravenous inhibitor of CDK4 and CDK6 while preserving HSPC and improving the functionality of the immune system during chemotherapy. Initial data from the company’s clinical phases is expected to be released in early 2018. The company’s second product candidate, G1T38, is expected to enter into phase two clinical trials in 2018. The company is based in North Carolina.
Executive management team
Mark A. Velleca, M.D., Ph.D. has served as the president, chief executive officer and board member of G1 Therapeutics since May 2014. Before that, Velleca co-founded and served as the senior vice president of CGI Pharmaceuticals Inc. from 1999 to 2010 until its acquisition by Gilead. He then served as a senior advisor to Gilead from 2010 until April 2012. From April 2012 to April 2014, Velleca served as the executive vice president of the Leukemia & Lymphoma Society. Velleca holds a Bachelor of Science from Yale University and an M.D. and Ph.D. from Washington University in St. Louis.
